Article Search
검색
검색 팝업 닫기

Metrics

Help

  • 1. Aims and Scope

    Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE

  • 2. Editorial Board

    Editor-in-Chief + MORE

    Editor-in-Chief
    Yong Chan Lee Professor of Medicine
    Director, Gastrointestinal Research Laboratory
    Veterans Affairs Medical Center, Univ. California San Francisco
    San Francisco, USA

    Deputy Editor

    Deputy Editor
    Jong Pil Im Seoul National University College of Medicine, Seoul, Korea
    Robert S. Bresalier University of Texas M. D. Anderson Cancer Center, Houston, USA
    Steven H. Itzkowitz Mount Sinai Medical Center, NY, USA
  • 3. Editorial Office
  • 4. Articles
  • 5. Instructions for Authors
  • 6. File Download (PDF version)
  • 7. Ethical Standards
  • 8. Peer Review

    All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
    The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.

    The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.

Search

Search

Year

to

Article Type

ahead

Split Viewer

Online first

Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year

Ik Hyun Jo1 , Kang-Moon Lee1 , Dae Bum Kim1 , Ji Won Kim2 , Jun Lee3 , Yoon Tae Jeen4 , Tae-Oh Kim5 , Joo Sung Kim6 , Jae Jun Park7 , Sung Noh Hong8 , Dong Il Park9 , Hyun-Soo Kim10 , Yoo Jin Lee11 , and Youngdoe Kim12

1Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, 2Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, 3Department of Internal Medicine, Chosun University Hospital, Gwangju, 4Department of Internal Medicine, Korea University Anam Hospital, Seoul, 5Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, 6Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 7Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 8Department of Internal Medicine, Samsung Medical Center, 9Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, 10Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju, 11Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, and 12Clinical Research Science Team, Medical Affairs, Janssen Korea Ltd., Seoul, Korea

Correspondence to:Kang-Moon Lee
ORCID https://orcid.org/0000-0003-2850-4553
E-mail drmaloman@catholic.ac.kr

Received: March 30, 2021; Revised: May 10, 2021; Accepted: June 14, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gut and Liver

Published online August 11, 2021

Copyright © Gut and Liver.

Abstract

Background/Aims: Improving quality of life has been gaining importance in ulcerative colitis (UC) management. The aim of this study was to investigate changes in health-related quality of life (HRQL) and related factors in patients with moderate-to-severe UC.
Methods: A multicenter, hospital-based, prospective study was performed using a Moderateto- Severe Ulcerative Colitis Cohort in Korea (the MOSAIK). Changes in HRQL, evaluated using the 12-Item Short Form Health Survey (SF-12) and Inflammatory Bowel Disease Questionnaire (IBDQ), were analyzed at the time of diagnosis and 1 year later.
Results: In a sample of 276 patients, the mean age was 38.4 years, and the majority of patients were male (59.8%). HRQL tended to increase in both the IBDQ and SF-12 1 year after diagnosis. A higher partial Mayo score was significantly related to poorer HRQL on the IBDQ and SF-12 in a linear mixed model (p<0.01). Inflammatory markers such as C-reactive protein (CRP) or erythrocyte sedimentation rate also showed a negative correlation on HRQL (p<0.05). Patients whose IBDQ score improved by 16 or more (71.2%) in 1 year were younger, tended to be nonsmokers, and had a lower partial Mayo score and CRP than those whose IBDQ score did not. There was no significant association between HRQL and disease extent, treatments at diagnosis, or the highest treatment step during the 1-year period.
Conclusions: Optimally controlled disease status improves HRQL in patients with moderate-tosevere UC. The partial Mayo score and inflammatory markers may be potential indicators reflecting the influence of UC on patient`s daily lives.

Keywords: Colitis, ulcerative, Quality of life, Treatment outcome, Cohort studies


Article

ahead

Gut and Liver

Published online August 11, 2021

Copyright © Gut and Liver.

Quality of Life in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: Changes in the MOSAIK Cohort Over 1 Year

Ik Hyun Jo1 , Kang-Moon Lee1 , Dae Bum Kim1 , Ji Won Kim2 , Jun Lee3 , Yoon Tae Jeen4 , Tae-Oh Kim5 , Joo Sung Kim6 , Jae Jun Park7 , Sung Noh Hong8 , Dong Il Park9 , Hyun-Soo Kim10 , Yoo Jin Lee11 , and Youngdoe Kim12

1Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, 2Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, 3Department of Internal Medicine, Chosun University Hospital, Gwangju, 4Department of Internal Medicine, Korea University Anam Hospital, Seoul, 5Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, 6Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 7Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 8Department of Internal Medicine, Samsung Medical Center, 9Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, 10Department of Internal Medicine, Wonju Severance Christian Hospital, Wonju, 11Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, and 12Clinical Research Science Team, Medical Affairs, Janssen Korea Ltd., Seoul, Korea

Correspondence to:Kang-Moon Lee
ORCID https://orcid.org/0000-0003-2850-4553
E-mail drmaloman@catholic.ac.kr

Received: March 30, 2021; Revised: May 10, 2021; Accepted: June 14, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background/Aims: Improving quality of life has been gaining importance in ulcerative colitis (UC) management. The aim of this study was to investigate changes in health-related quality of life (HRQL) and related factors in patients with moderate-to-severe UC.
Methods: A multicenter, hospital-based, prospective study was performed using a Moderateto- Severe Ulcerative Colitis Cohort in Korea (the MOSAIK). Changes in HRQL, evaluated using the 12-Item Short Form Health Survey (SF-12) and Inflammatory Bowel Disease Questionnaire (IBDQ), were analyzed at the time of diagnosis and 1 year later.
Results: In a sample of 276 patients, the mean age was 38.4 years, and the majority of patients were male (59.8%). HRQL tended to increase in both the IBDQ and SF-12 1 year after diagnosis. A higher partial Mayo score was significantly related to poorer HRQL on the IBDQ and SF-12 in a linear mixed model (p<0.01). Inflammatory markers such as C-reactive protein (CRP) or erythrocyte sedimentation rate also showed a negative correlation on HRQL (p<0.05). Patients whose IBDQ score improved by 16 or more (71.2%) in 1 year were younger, tended to be nonsmokers, and had a lower partial Mayo score and CRP than those whose IBDQ score did not. There was no significant association between HRQL and disease extent, treatments at diagnosis, or the highest treatment step during the 1-year period.
Conclusions: Optimally controlled disease status improves HRQL in patients with moderate-tosevere UC. The partial Mayo score and inflammatory markers may be potential indicators reflecting the influence of UC on patient`s daily lives.

Keywords: Colitis, ulcerative, Quality of life, Treatment outcome, Cohort studies

Gut and Liver

Vol.15 No.5
September, 2021

pISSN 1976-2283
eISSN 2005-1212

qrcode
qrcode

Share this article on :

  • line

Popular Keywords

Gut and LiverQR code Download
qr-code

Editorial Office